Bismuth subsalicylate for gastrointestinal symptoms
Pro Research Analysisby 
Searched over 200M research papers
Bismuth Subsalicylate for Diarrhea and Gastroenteritis Relief
Bismuth subsalicylate (BSS) is widely recognized for its effectiveness in treating and preventing various gastrointestinal symptoms, especially diarrhea. Studies have shown that BSS can significantly reduce the number of stools and improve subjective symptoms in patients with traveler's diarrhea, chronic infantile diarrhea, and Norwalk virus-induced gastroenteritis. It is also effective in preventing traveler's diarrhea, with efficacy rates ranging from 62% to 76% depending on the formulation and dosage used. The salicylate component of BSS provides antisecretory effects, while bismuth and its hydrolysis products have direct antimicrobial actions, making it beneficial for both treatment and prevention of infectious diarrhea, including that caused by enterotoxigenic Escherichia coli and Norwalk virus 1567+1 MORE.
Bismuth Subsalicylate for Indigestion and Gastrointestinal Discomfort
BSS has demonstrated superior relief compared to placebo for symptoms of indigestion, such as nausea, sense of fullness, heartburn, abdominal distention, and flatulence. In controlled studies, patients experienced faster and more complete relief from these symptoms when treated with BSS, although it was not significantly more effective for upper abdominal pain. BSS also provided significant relief from gastrointestinal discomfort following excessive food and alcohol intake, with no reported adverse reactions in these studies 2348.
Bismuth Subsalicylate for Medication-Related Gastrointestinal Symptoms
In individuals experiencing gastrointestinal side effects from medications such as delayed-release dimethyl fumarate (used for multiple sclerosis), BSS did not reduce the overall occurrence of GI events but did lower the severity and incidence of flatulence and diarrhea compared to placebo .
Safety and Recommendations for Use
BSS is generally considered safe for short-term use, with low rates of adverse reactions reported in clinical trials. However, prolonged use of bismuth-containing compounds has been associated with rare cases of neurological toxicity, so treatment periods should not exceed 6–8 weeks, followed by bismuth-free intervals. BSS is also valued for its role in treating peptic ulcers and eradicating Helicobacter pylori, addressing both symptoms and underlying causes of gastrointestinal disease 78.
Conclusion
Bismuth subsalicylate is an effective and safe option for the treatment and prevention of a range of gastrointestinal symptoms, including diarrhea, indigestion, and discomfort from overeating or medication side effects. Its dual action—antisecretory and antimicrobial—makes it particularly useful for infectious diarrhea and traveler's diarrhea. Short-term use is recommended to minimize the risk of rare adverse effects.
Sources and full results
Most relevant research papers on this topic